“Meowzempic” Arrives: New Weight-Loss Drugs for Cats Mirror Ozempic’s Success
Table of Contents
A growing pet healthcare market is poised to welcome a new wave of weight-loss solutions for feline companions, mirroring the impact of human drugs like Ozempic. Chinese pharmaceutical companies, alongside US-based biopharmaceutical firms, are developing glucagon-like peptide-1 (GLP-1) receptor agonists designed to curb appetite and promote weight loss in cats.
China is leading the charge, with Huadong Medicine and YaoPharma both nearing the launch of their respective drugs. These medications function by mimicking GLP-1, a naturally occurring hormone that regulates blood sugar and suppresses appetite. The drugs signal to the brain that the animal is full, leading to reduced food intake – a mechanism similar to that of Ozempic in humans.
The need for such treatments is becoming increasingly apparent. China’s pet population has exploded in recent years, surging from approximately 310 million in 2020 to over 430 million in 2024, according to Shanghai’s City News Service. Of these, roughly 71 million are cats, with a significant 28% classified as overweight. Currently, no drugs are specifically approved globally to address feline obesity, creating a substantial market opportunity.
Huadong Medicine’s drug has shown promising results in trials. Cats participating in the studies experienced an average weight loss of 9% over six weeks, with nearly 75% losing more than 5% of their body weight. Importantly, no adverse side effects were reported during the once-weekly injectable treatment. The drug received formal acceptance for review by China’s Ministry of Agriculture and Rural Affairs on December 26, 2025.
Pfizer Invests in Veterinary GLP-1 Research
Meanwhile, YaoPharma, a subsidiary of Fosun Pharma, secured a substantial $2.1 billion (S$2.7 billion) licensing deal with Pfizer in December 2025 to develop and commercialize its own GLP-1-based obesity pill. A company release indicated the license covers both human and veterinary applications. Pfizer has already made an initial payment of $150 million, but the drug is still in early-stage clinical trials in Australia, meaning it will likely take several years to reach the market, pending successful trial outcomes.
Across the globe, San Francisco-based Okava Pharmaceuticals is also pursuing a GLP-1 solution for obese cats. On December 2, the company announced the commencement of a pilot study for MEOW-1, short for “ManagEment of Over Weight cats.” Unlike the weekly injections offered by Huadong’s drug, MEOW-1 utilizes a slow-release injectable implant, slightly larger than a microchip, designed to deliver the medication for up to six months.
Rising Obesity Rates Fuel Demand for Pet Weight Management
The development of these drugs comes as pet obesity rates continue to climb. A veterinarian at the University of Florida, Dr. Chen Gilor, recently told The New York Times that roughly 60% of cats and dogs in the US are obese, with hundreds of thousands also suffering from diabetes. Okava Pharmaceuticals highlights the potential of MEOW-1 to “enhance quality of life, promote healthy ageing, and become the most impactful life-extending therapy available for cats.”
Currently, some veterinarians are already administering human GLP-1 drugs off-label to diabetic cats, but the cost – hundreds of dollars per month – is equivalent to the price of human treatment. These existing options also haven’t proven entirely effective in replacing insulin for cats with advanced diabetes.
Despite the promise, questions remain regarding affordability and appeal. A veterinary nutritionist at the University of Tennessee, Dr. Maryanne Murphy, cautioned that GLP-1 drugs should be viewed as a supplement to, rather than a replacement for, traditional weight management strategies. “I think it would not be a simple, quick, easy fix, where you just give the medication and you do not have to worry about anything else,” she stated.
As large-scale clinical trials progress, the future of these feline weight-loss drugs remains to be seen, but the growing demand for effective solutions suggests a significant market opportunity in the evolving landscape of pet healthcare.
Keep reading
